https://globaleprism.com/health/2026/09/07/63492/novo-nordisk-halts/
Novo Nordisk Halts Ziltivekimab Trials in Setback for Heart Pipeline 2026 - GlobalePrism
Sep 7, 2026 - Novo Nordisk has halted two Phase 3 trials of its cardiovascular drug ziltivekimab due to futility, marking a major pipeline diversification setback.
novo nordiskhaltsziltivekimabtrialssetback
https://research.hub.ku.edu.tr/entities/publication/db92d31c-52b9-4cbb-9fb1-d314d12a6337
Ziltivekimab for anemia and atherosclerosis in chronic kidney disease: a new hope?
Anemia of chronic kidney disease is a multifactorial condition secondary to various etiologies, including nutritional deficiencies, chronic inflammation,...
chronic kidney diseasenew hopeziltivekimabanemiaatherosclerosis
https://allsci.com/news/clinical-trials/ziltivekimab-phase-iii-trials-stopped-novo/
Novo Nordisk scraps two Phase III ziltivekimab trials after ZEUS failure
Sep 8, 2026 - Novo Nordisk halts Phase III ziltivekimab trials (HERMES, ATHENA) for heart failure after futility signal. Read the latest update on this IL-6 inhibitor...
novo nordisktwo phasescrapsiiiziltivekimab